Effect of implantation of Augment(®) Bone Graft on serum concentrations of platelet-derived growth factors: a pharmacokinetic study
| Autor: | Stephen Roach, Leo B. Snel, William Beasley, Timothy R. Daniels, Luis A. Solchaga |
|---|---|
| Rok vydání: | 2013 |
| Předmět: |
Adult
Calcium Phosphates Male medicine.medical_specialty Platelet-derived growth factor Time Factors medicine.medical_treatment Arthrodesis Urology Becaplermin Biocompatible Materials Enzyme-Linked Immunosorbent Assay chemistry.chemical_compound Pharmacokinetics medicine Humans Pharmacology (medical) Platelet Aged Platelet-Derived Growth Factor business.industry Growth factor General Medicine Proto-Oncogene Proteins c-sis Serum concentration Middle Aged Surgery surgical procedures operative medicine.anatomical_structure chemistry Female Ankle business Ankle Joint medicine.drug |
| Zdroj: | Clinical drug investigation. 33(2) |
| ISSN: | 1179-1918 |
| Popis: | Augment(®) Bone Graft is a bone graft substitute intended to be used as an alternative to autologous bone graft in the fusion of hindfoot and ankle joints. Augment(®) Bone Graft is a combination device comprised of beta-tricalcium phosphate (β-TCP) and recombinant human platelet-derived growth factor BB homodimer (rhPDGF-BB).This human pharmacokinetic study was undertaken to assess the effect of Augment(®) Bone Graft implantation on the serum concentration of platelet-derived growth factors (PDGFs).Under the terms of a Research Ethics Board-approved protocol, Augment(®) Bone Graft was implanted in patients (n = 7) undergoing hindfoot and ankle arthrodesis procedures requiring graft material. The control cohort of the study (n = 4) received autologous bone graft. The serum concentrations of PDGF isoforms AA, AB and BB in blood samples, obtained prior to and at ten time points (up to 7 days) after surgery, were measured using enzyme-linked immunosorbent assays (ELISA).The serum concentration of PDGF-BB did not vary significantly from baseline (median of the combined cohorts 3.89 ng/mL) throughout the course of the study. The serum concentrations of PDGF-AA, PDGF-AB and total PDGF did not deviate from their baseline values (medians of the combined cohorts were 2.87, 14.95 and 20.19 ng/mL for PDGF-AA, PDGF-AB and total PDGF, respectively) except for the last time point in which they were increased (medians for the combined cohorts were 4.71, 20.42 and 30.29 ng/mL for PDGF-AA, PDGF-AB and total PDGF, respectively). There were no differences between the two treatment groups with regard to changes in the serum concentrations of PDGF. None of the samples tested contained anti-PDGF-BB antibodies.Analysis of the data demonstrated that the serum concentrations of all three PDGF isoforms analysed were unaffected by implantation of Augment(®) Bone Graft. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink